Bhaskar Chaudhuri, Ph.D.

Bhaskar joined Frazier in 2011 and brings to the Life Sciences team significant operational experience in drug research, development, and commercialization in the United States, Europe, and emerging markets. He leads investments in later-stage companies and in international opportunities and is a co-founder of Arcutis Biotherapeutics (NASDAQ: ARQT), where he serves on the board of directors. Bhaskar also serves on the board of Tarsus Pharmaceuticals (NASDAQ:TARS), and also served on the board of Silvergate Pharmaceuticals (acquired by CutisPharma), Corium International (NASDAQ: CORI) which was acquired by Gurnet Point Capital and Thesan Pharmaceuticals.

Prior to joining Frazier, Bhaskar was President of Valeant Pharmaceuticals, where he led Valeant’s international operations and business development activities. He joined Valeant through its acquisition of Dow Pharmaceutical Sciences, where he had been President and CEO. Dow focused on dermatology drug development and commercialization, and was the source of multiple approved products including Jublia for onychomycosis and Acanya for acne. Before Dow, Bhaskar worked at Mylan Pharmaceuticals in several capacities including EVP of Scientific Affairs at Mylan subsidiary Bertek Pharmaceuticals, and as General Manager of the Dermatology Division. Earlier, he worked at Penederm, a skin-products and drug-delivery company, as VP of R&D.

Bhaskar also serves on an Advisory Board at John’s Hopkins Institute of Bioethics and the School of Pharmacy Innovation Center at the University of the Pacific.

Bhaskar holds a Ph.D. from the University of Louisiana, a M.S. in Industrial Pharmacy from Jadavpur University, India and a B.S. in Pharmacy from Jadavpur University.